Molina Healthcare
MOH
194.82
-0.35
-0.18%
Molina Healthcare
US · MOH
#1475 by market cap
Listed 1970
194.82
-0.35
-0.18%
Live - 5344 symbols - heartbeat 414s ago
· 2026-10-08 07:31
Pre-market
193.00
-0.93%
After-hours
194.82
0.00%
- Market cap
- 10.17B
- P/E (TTM)i
- 1,025.37
- P/Bi
- 2.44
- EPSi
- 8.92
- Div yieldi
- 0.00%
- 52W posi
- 60%
Reader sentiment
Are you bullish or bearish on MOH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.33, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +11.75% YoY
Margins
- Gross margin
- 8.97%
- Operating margin
- 1.72%
- Net margin
- 1.04%
Key ratios & quality
- Altman Z-Scorei
- 4.33
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.89B | 16.83B | 19.42B | 27.77B | 31.97B | 34.07B | 40.65B | 45.43B |
| Gross profit | 2.62B | 2.44B | 2.68B | 3.28B | 3.93B | 4.33B | 4.74B | 4.08B |
| Selling & admin expenses | 1.33B | 1.30B | 1.48B | 2.07B | 2.31B | 2.46B | 2.74B | 3.01B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.13B | 1.04B | 1.08B | 1.02B | 1.38B | 1.57B | 1.71B | 781.00M |
| Pretax profit | 999.00M | 972.00M | 961.00M | 875.00M | 1.06B | 1.46B | 1.59B | 589.00M |
| Tax | 292.00M | 235.00M | 288.00M | 216.00M | 271.00M | 373.00M | 410.00M | 117.00M |
| Net profit | 707.00M | 737.00M | 673.00M | 659.00M | 792.00M | 1.09B | 1.18B | 472.00M |
| Basic EPS | 12 | 12 | 11 | 11 | 14 | 19 | 21 | 9 |
| Diluted EPS | 10.61 | 11.47 | 11.23 | 11.25 | 13.55 | 18.77 | 20.42 | 8.92 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 11.15B | 11.43B | 11.48B | 11.38B | 10.80B | 10.87B |
| Gross profit | 1.28B | 1.17B | 927.00M | 701.00M | 1.02B | 929.00M |
| Selling & admin expenses | 774.00M | 711.00M | 729.00M | 795.00M | 779.00M | 724.00M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 433.00M | 373.00M | 137.00M | -162.00M | 176.00M | 145.00M |
| Pretax profit | 390.00M | 325.00M | 88.00M | -214.00M | 29.00M | 91.00M |
| Tax | 92.00M | 70.00M | 9.00M | -54.00M | 15.00M | 31.00M |
| Net profit | 298.00M | 255.00M | 79.00M | -160.00M | 14.00M | 60.00M |
| Basic EPS | 5 | 5 | 2 | -3 | 0 | 1 |
| Diluted EPS | 5.45 | 4.75 | 1.51 | -3.15 | 0.27 | 1.19 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 6.46B | 5.97B | 7.88B | 10.06B | 10.08B | 12.54B | 12.77B | 12.44B |
| Cash & ST investments | 4.51B | 4.40B | 6.03B | 7.64B | 7.51B | 9.11B | 8.99B | 8.26B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 7.15B | 6.79B | 9.53B | 12.21B | 12.31B | 14.89B | 15.63B | 15.56B |
| Total current liabilities | 4.25B | 3.27B | 4.97B | 7.05B | 6.86B | 8.17B | 7.90B | 7.37B |
| Short-term debt | 241.00M | -- | -- | -- | -- | -- | -- | -- |
| Long-term debt | 1.02B | 1.24B | 2.13B | 2.17B | 2.18B | 2.18B | 2.92B | 3.77B |
| Total liabilities | 5,507,000,000.00 | 4,827,000,000.00 | 7,436,000,000.00 | 9,579,000,000.00 | 9,350,000,000.00 | 10,677,000,000.00 | 11,134,000,000.00 | 11,495,000,000.00 |
| Total equity | 1.65B | 1.96B | 2.10B | 2.63B | 2.96B | 4.22B | 4.50B | 4.07B |
| Retained earnings | 1.01B | 1.78B | 1.86B | 2.40B | 2.80B | 3.89B | 4.09B | 3.60B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 13.26B | 13.11B | 12.55B | 12.44B | 13.33B | 12.93B |
| Cash & ST investments | 9.29B | 8.81B | 8.45B | 8.26B | 9.25B | 8.92B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 16.39B | 16.21B | 15.70B | 15.56B | 16.39B | 16.00B |
| Total current liabilities | 8.16B | 7.88B | 7.48B | 7.37B | 8.19B | 7.70B |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | 3.57B | 3.38B | 3.66B | 3.77B | 3.77B | 3.77B |
| Total liabilities | 12,076,000,000.00 | 11,606,000,000.00 | 11,507,000,000.00 | 11,495,000,000.00 | 12,311,000,000.00 | 11,832,000,000.00 |
| Total equity | 4.31B | 4.60B | 4.19B | 4.07B | 4.08B | 4.17B |
| Retained earnings | 3.90B | 4.16B | 3.76B | 3.60B | 3.62B | 3.68B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -314.00M | 434.00M | 1.90B | 2.12B | 773.00M | 1.66B | 644.00M | -535.00M |
| Depreciation & amortization | 127.00M | 89.00M | 88.00M | 131.00M | 176.00M | 171.00M | 186.00M | 195.00M |
| Free cash flow | -344.00M | 377.00M | 1.82B | 2.04B | 682.00M | 1.58B | 544.00M | -636.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | -47.00M | -606.00M | -128.00M | -400.00M | 0 | -1.00B | -1.00B |
| Ending cash balance | 2.93B | 2.51B | 4.22B | 4.51B | 4.05B | 4.91B | 4.74B | 4.35B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 190.00M | -302.00M | -125.00M | -298.00M | 1.08B | -294.00M |
| Depreciation & amortization | 48.00M | 58.00M | 45.00M | 44.00M | 39.00M | 40.00M |
| Free cash flow | 168.00M | -344.00M | -163.00M | -297.00M | 1.06B | -324.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -500.00M | 0 | -500.00M | 0 | 0 | 0 |
| Ending cash balance | 4.96B | 4.59B | 4.32B | 4.35B | 5.42B | 5.09B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 47.39 | 40.87 | 33.19 | 27.89 | 28.32 | 30.39 | 27.07 | 11.02 |
| ROA %i | 9.05 | 10.57 | 8.25 | 6.06 | 6.46 | 8.02 | 7.73 | 3.03 |
| ROIC %i | 23.85 | 24.51 | 18.90 | 15.83 | 16.84 | 19.61 | 17.82 | 8.01 |
| 5-year avg ROE %i | 6.80 | 13.67 | 18.08 | 23.01 | 35.53 | 32.13 | 29.37 | 24.94 |
| EBIT margin %i | 5.90 | 6.29 | 5.47 | 3.58 | 3.67 | 4.62 | 4.20 | 1.72 |
| FCF / sales %i | -- | 2.20 | 9.35 | 7.35 | 2.13 | 4.63 | 1.34 | -- |
| Current ratioi | 1.52 | 1.83 | 1.59 | 1.43 | 1.47 | 1.54 | 1.62 | 1.69 |
| Quick ratioi | 1.37 | 1.78 | 1.55 | 1.39 | 1.43 | 1.49 | 1.56 | 1.60 |
| Debt / assetsi | 20.38 | 21.63 | 24.67 | 19.59 | 19.42 | 16.02 | 19.95 | 25.38 |
| LT debt / equityi | 73.89 | 74.90 | 112.21 | 90.95 | 80.67 | 56.58 | 69.35 | 97.08 |
| Interest coveragei | 9.69 | 12.17 | 10.42 | 8.29 | 10.66 | 14.43 | 14.47 | 4.07 |
| Revenue CAGR (3Y) %i | 10.04 | -1.82 | -0.78 | 13.71 | 23.85 | 20.60 | 13.54 | 12.42 |
| Net income CAGR (3Y) %i | 70.36 | 142.00 | -- | -2.32 | 2.43 | 17.47 | 21.40 | -15.85 |
| FCF CAGR (3Y) %i | -- | -8.80 | 36.45 | -- | 21.85 | -4.71 | -35.66 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 26.72 | 23.93 | 19.71 | 11.02 | 4.48 | -0.16 |
| ROA %i | 7.37 | 7.20 | 5.61 | 3.03 | 1.15 | -0.04 |
| ROIC %i | 17.07 | 16.19 | 13.25 | 8.01 | 4.41 | 1.45 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 4.09 | 3.81 | 2.97 | 1.72 | 0.96 | 0.46 |
| FCF / sales %i | 1.25 | 0.98 | -- | -- | 0.56 | 0.61 |
| Current ratioi | 1.63 | 1.66 | 1.68 | 1.69 | 1.63 | 1.68 |
| Quick ratioi | 1.57 | 1.61 | 1.60 | 1.60 | 1.55 | 1.61 |
| Debt / assetsi | 22.98 | 21.98 | 24.54 | 25.38 | 24.08 | 24.70 |
| LT debt / equityi | 87.38 | 77.41 | 91.91 | 97.08 | 96.74 | 94.77 |
| Interest coveragei | 12.79 | 10.73 | 7.60 | 4.07 | 2.12 | 0.97 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Medicaid is the largest reported line at 74.02% of revenue, across 5 reported segments.
- The next-largest line, Medicare, is a distant second at 14.39% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Medicaid74.02%
Medicare14.39%
Marketplace5.78%
Other Operating Revenues5.57%
Other0.24%
Quote time 2026-10-08 07:31:48 · For reference only, not investment advice and not tailored to your situation.